- Видео 73
- Просмотров 16 600
PSYCH
Добавлен 16 апр 2021
PSYCH is a premium business-to-business media and content platform for the psychedelic science and healthcare industry.
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace.
We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
To learn more about us, access our industry-leading events, subscribe to the most widely read psychedelics industry newsletter, or view our insight-rich Psychedelics as Medicine Report:
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace.
We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
To learn more about us, access our industry-leading events, subscribe to the most widely read psychedelics industry newsletter, or view our insight-rich Psychedelics as Medicine Report:
PSYCH Symposium: Shifting Perceptions - in conversation with Professor Robin Carhart-Harris
A fully regulated psychedelic medicine industry has arguably never been closer. The ecosystem is already in place, waiting for the legislatorial dial to move. If widespread regulation arrived tomorrow, what would happen next? From worldwide mental health through to perhaps even political discourse, how would various sections of society be affected; and are they ready for it?
At PSYCH symposium, this one-on-one interview between journalist Kate Spicer and the pioneering Prof. Robin Carhart-Harris explored the possible realities of psychedelics as part of our societal fabric.
At PSYCH symposium, this one-on-one interview between journalist Kate Spicer and the pioneering Prof. Robin Carhart-Harris explored the possible realities of psychedelics as part of our societal fabric.
Просмотров: 1 589
Видео
PSYCH Symposium: Solutions for police are solutions for society
Просмотров 83Год назад
There is a growing political crisis with falling public confidence in police, in the UK, the EU, and around the world. This is an opportunity to shift public and political perceptions as to the solutions, as the crisis in policing can not be solved without solving the mental health crisis in policing. The secret to preparing and growing a market is identifying the need. Solutions follow. With a...
PSYCH Symposium: Clearing a Path for Treatment
Просмотров 161Год назад
With both an increase in psychedelic clinical trials and adoption of new regulations allowing access to psychedelic therapies, the need for trained facilitators and therapists who can provide these services becomes vital. Drawing on the recent developments in policy, this PSYCH Symposium panel discussed the urgency of companies needing to train therapists before this becomes a roadblock for pat...
PSYCH Symposium: Atlantic Psychedelics - From Discovery to Delivery
Просмотров 109Год назад
PSYCH Symposium's Atlantic Psychedelic panel explored the complexities that psychedelic compounds bring to drug development and speak of their experience on both sides of the Atlantic (US, Canada and UK) and within the Commonwealth (Australia). Featuring: George McBride, Chief Commercial Officer, Clerkenwell Health. Clare Knight, Senior Clinical Trials Manager, Clerkenwell Health. Nicholas Kady...
PSYCH Symposium: Neuroimaging and Psychedelics
Просмотров 133Год назад
A panel of experts explored the key neuroimaging findings to date, and how neuroimaging technologies can support and accelerate both our knowledge of psychedelic brain mechanisms, and the clinical development of associated therapies. Featuring: Dr. Chris Timmermann, Psychedelic Research Clinician, Imperial College London. Beata Godlewska, Clinical Researcher, Department of Psychology, Oxford Un...
PSYCH Symposium: The Future of Psychedelic Medicine in the EU
Просмотров 167Год назад
There is a growing belief that research around the potential of psychedelics is finally making key policymakers within the European Parliament stand up and take notice. With organisations like PAREA now facilitating meaningful conversations which could lead to a shift in perception, how could the EU take a central role in driving psychedelic healthcare to become a reality across Europe? PSYCH S...
PSYCH Symposium: Reassessing the Psychedelic Space
Просмотров 687Год назад
In the psychedelic sector a period of unabashed exuberance has given way to a sobering couple of years, with company valuations and investment tumbling amidst broader economic turmoil. Despite this challenging financial backdrop, a first-in-class psychedelic-assisted therapy could be approved as early as next year and public interest in these substances shows no sign of slowing. In this firesid...
PSYCH Symposium: Understanding institutional investors’ interest in psychedelics
Просмотров 102Год назад
Institutional investors are interested in the psychedelic medicine sector but they are not investing. So, what is holding them back and what would encourage them to take an equity position? FTI Consulting issued a survey to institutional investors in the UK and US to understand their level of interest in the sector, how they expect the sector to perform in the coming years and what are the cata...
PSYCH Symposium: Access to Psychedelic Medicines
Просмотров 182Год назад
PSYCH Symposium 2023 saw a panel of experts discuss the reality of the new psychedelic market and the complicated framework healthcare professionals and policymakers need to work within, whilst also looking at what we can learn from recent developments in Australia. Featuring: Dr. Farrah Jarral, Writer, Broadcaster and GP. Dr. Guy Goodwin, Chief Medical Officer, COMPASS Pathways. Charlotte Nich...
PSYCH Symposium: Ketamine assisted therapy to treat addiction
Просмотров 260Год назад
Professor Celia Morgan speaks about Awakn Life Sciences' programmes of research investigating ketamine-assisted therapy across AUD and behavioural addictions, which together have aimed to develop an efficient treatment that will be easy to implement in existing healthcare systems.
PSYCH Symposium: Challenges in Psychedelic Drug Development
Просмотров 98Год назад
Challenges in Psychedelic Drug Development: Psychedelics induce non-ordinary states of consciousness, which creates unique challenges in the design and conduct of research studies. This panel of experts explored some of the key challenges that are critical to good clinical development in this space. Featuring: Dr. Amir Inamdar, Chief Medical Officer, Cybin Inc. Dr. Catherine Schuster-Bruce, Jou...
PSYCH Symposium: Treating eating disorders
Просмотров 134Год назад
Building patterns and reducing prevalence: PSYCH Symposium explores how psychedelics can create potential mechanisms for the brain to cope with the key triggers of eating disorders. Featuring: Rivki Stern, CEO, Shortwave Pharma. Professor Rebecca Park, Associate Professor & Honorary, Consultant Psychiatrist, Speaker, Oxford University. Yoel Golbert, Clinical Psychologist and Psychedelic Researc...
PSYCH Symposium: Shortwave Opening Remarks
Просмотров 42Год назад
PSYCH Symposium: Shortwave Opening Remarks
PSYCH Symposium | Dr Anne Schlag
Просмотров 33Год назад
Join experts and thought leaders at PSYCH Symposium on 6 July at the British Museum.
Measuring Ketamine’s Efficacy with Neuroimaging | PSYCH Symposium: London 2022
Просмотров 2242 года назад
Measuring Ketamine’s Efficacy with Neuroimaging | PSYCH Symposium: London 2022
How Can We Promote Public Education and Patient Accessibility? | PSYCH Symposium: London 2022
Просмотров 1192 года назад
How Can We Promote Public Education and Patient Accessibility? | PSYCH Symposium: London 2022
How Can Investors Benefit from a Bear Market? | Christian Angermayer | PSYCH Symposium: London 2022
Просмотров 2612 года назад
How Can Investors Benefit from a Bear Market? | Christian Angermayer | PSYCH Symposium: London 2022
When will MDMA-assisted therapy be available in Europe? | Rick Doblin | PSYCH Symposium: London 2022
Просмотров 3822 года назад
When will MDMA-assisted therapy be available in Europe? | Rick Doblin | PSYCH Symposium: London 2022
The Psychedelic Renaissance: A Family Affair | PSYCH Symposium: London 2022
Просмотров 4362 года назад
The Psychedelic Renaissance: A Family Affair | PSYCH Symposium: London 2022
A Surge in Synthetic Psychedelic Medicines | PSYCH Symposium: London 2022
Просмотров 2942 года назад
A Surge in Synthetic Psychedelic Medicines | PSYCH Symposium: London 2022
Accessing Psilocybin in the UK | Crispin Blunt MP | PSYCH Symposium: London 2022
Просмотров 3202 года назад
Accessing Psilocybin in the UK | Crispin Blunt MP | PSYCH Symposium: London 2022
Psychedelic Healthcare Without Hallucinations | Professor Bryan Roth | PSYCH Symposium: London 2022
Просмотров 3502 года назад
Psychedelic Healthcare Without Hallucinations | Professor Bryan Roth | PSYCH Symposium: London 2022
How Integral is Patient Integration? | PSYCH Symposium: London 2022
Просмотров 4412 года назад
How Integral is Patient Integration? | PSYCH Symposium: London 2022
The Psychedelic Medicines of Tomorrow | PSYCH Symposium: London 2022
Просмотров 2412 года назад
The Psychedelic Medicines of Tomorrow | PSYCH Symposium: London 2022
Fighting PTSD with Psychedelic Healthcare | PSYCH Symposium: London 2022
Просмотров 1072 года назад
Fighting PTSD with Psychedelic Healthcare | PSYCH Symposium: London 2022
Rumination and Escaping Depression | Professor David Nutt | PSYCH Symposium: London 2022
Просмотров 1,7 тыс.2 года назад
Rumination and Escaping Depression | Professor David Nutt | PSYCH Symposium: London 2022
Was going to say. Guy has bin around awhile
Thomas M. Ling M.A., M.D., M.R.C.P at Marlborough Day Hospital, London & John Buckman M.R.C.S., L.R.C.P., D.P.M. Marlborough Day Hospital conducted excellent research on LSD & Anxiety 60 years ago. Not sure why these younger researchers overlook the literature and keep stumbling over covered ground(?) this research was heavily covered decades ago! LSD works incredibly well for Anxiety, we’ve known this for 60 years!
❤❤❤❤❤ 11:58
Nematodes are boring? Cox is a rockstar scientist? You wouldn't say this interviewer has her finger on the pulse exactly. 😂
I think sharing the experience from your psychiatric nurse colleague was a really good way of dropping in a very sensitive and poignant topic. Awesome as always keep up the good work. 👍
Professor Robin Carhart-Harris is the best.
'Promo SM' 😪
Pharmala Biotech does not manufacture anything, so that was a lie straight off the bat from Nicholas Kadysh, Founding CEO & President, PharmAla Biotech. Pharmala is just a MDMA middleman. "PharmAla is a research entity and does not physically possess any Controlled Substances. All work is completed by duly licensed laboratories." Taken from the bottom of the Pharmala website. Listen to Nick say Pharmala does not manufacture MDMA 16 May 2023 Psychedelics Today podcast PT410 - Nick Kadysh - Manufacturing MDMA and Why Creating MDMA Analogs Is So Important
The elves are happy with you fellas.
Also Leute ich unterstütze euch schon als Aktionär soweit es meine Möglichkeiten zulassen aber gibt bitte gas. Ich habe schon 5 Bekannten die Selbstmord begangen haben. Das wird langsam zu den häufigsten Todesursachen. Ich glaube an Euch!
If a surfer sitting on his surfboard doesn’t paddle like mad and get to his feet, the wave passes right on by. Yes, I realize we’re at that stage of counterbalancing a decade plus of glowing idealism about psychedelic experiences, but I hope we don’t devalue what, all things considered, is still as promising an addition to the western therapist’s tool kit as anything since the birth of therapy itself.
Having lost my father to alcoholism and ultimately suicide, I want to thank you all for your work in mental health! I hope more places take to decriminalizing and legalizing these wonderful medications.
Amazing work from wise humans!! What a shame such natural medicines have been banned for personal use. I pray this changes.
I got some from an online supplier, they are discreetly shipped
FROM TRIP_MYCOLOGIST
in instagram
Rick and other non-profits: please review law 13 in the book The 48 Laws of Power. This is not an endorsement of the book.
I hope taxes involved in this don't go towards persecuting traditional use. I don't mean to villainize anyone, but we must consider market forces long term--and if the rumor of COMPASS chasing things like patenting the use of couches in psychedelic therapy is true, we may have to consider it short-term as well. Mush Love
Really fantastic to see the channel has been so active over the last month, really enjoying the interviews and content! Keep up the amazing work.
ruclips.net/video/T2rMlc_0Cw4/видео.html
$MNMD 💪🏻
Hello!, keep up the work. You will enjoy this channel 👉 #drjohnaking. I find him encouraging and insightful.
Rip off company! I made a significant purchase two months ago and never received anything! I sent emails via Gwella's website to inquire about this, but nobody ever responded back to me.
These viddys are really good ya gonna keep it up? 🤔
giimme
I like the stock and I’m not a cat.
Rick Doblin is a legend ✊
Glad to be a small share hold I plan on buying more and holding. Keep up the good work y'all
High risk , big rewards for investors
…….another terrible company thats wants to use Psilocybin DERIVATIVES as a capital builder for Plutocratic Oligarch…f-you.
This is a great company, doing great things!
Psymposia is going to have a field day with this one
You mean have a field day with Atai buying off Doblin and owning Maps?
@@BushyHairedStranger Yes and Angermayer's characterisation of psychedelics as religious drugs
Patent trolling psychedelics and fighting against their legalization might be wise from a financial standpoint for Christian's company, but it is unwise if his intention is to democratize availability.
Great segment!
🙌🏼🙌🏼
Invaluable
Great info, thank you.